Key result
NGS reveals ~7-fold MYC amplification and PTPRD mutation in radiation-naive GI epithelioid angiosarcoma.
Why the study?
Primary gastrointestinal epithelioid angiosarcoma frequently mimics poorly differentiated carcinoma, and its molecular landscape, particularly regarding MYC status, remains underrecognized compared to radiation-associated angiosarcomas.
Case Report (n=1)
This case challenges the traditional view by demonstrating that MYC amplification can occur in primary epithelioid angiosarcoma without prior radiotherapy, potentially serving as a driver and biomarker for aggressive behavior.
MYC amplification may occur in radiotherapy-naive primary epithelioid angiosarcoma; hypothesis-generating for its role as driver or biomarker.
Primary gastrointestinal epithelioid angiosarcoma (EAS) is an extremely rare and aggressive malignancy. Due to its epithelioid morphology and aberrant cytokeratin expression, it frequently mimics poorly differentiated carcinoma, creating significant diagnostic challenges. Furthermore, the molecular landscape of primary EAS, particularly regarding MYC status, remains underrecognized compared to radiation-associated angiosarcomas. An 82-year-old man presented with refractory melena and severe anemia. Imaging revealed multifocal lesions involving the stomach and small intestine. The patient underwent a laparoscopic exploration and multiple segmental resections. Histologically, the tumors consisted of epithelioid cells arranged in solid sheets with extensive hemorrhage. Immunohistochemistry showed strong positivity for CD31, ERG, and CD34, accompanied by diffuse CKpan expression, mimicking carcinoma. Crucially, despite the absence of prior radiotherapy, Next-Generation Sequencing (NGS) of the gastric lesion identified significant MYC gene amplification (copy number 6.7) and a PTPRD nonsense mutation. The patient died three months after surgery. This case highlights a critical diagnostic pitfall: primary EAS can diffusely express cytokeratins. More importantly, our findings challenge the traditional view that MYC amplification is exclusive to secondary, radiation-associated angiosarcomas. We propose that MYC amplification can act as a driver in primary EAS and may serve as a biomarker for aggressive clinical behavior.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted a case report in Primary multifocal gastrointestinal epithelioid angiosarcoma (n=1). Next-Generation Sequencing and Immunohistochemistry was evaluated on Molecular and immunohistochemical characterization. Next-generation sequencing of a primary gastrointestinal epithelioid angiosarcoma revealed a 6.7-fold MYC amplification and a PTPRD nonsense mutation in a patient without prior radiation exposure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: